Clinical Trials
8
Active:0
Completed:4
Trial Phases
2 Phases
Phase 3:1
Phase 4:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 4
6 (85.7%)Phase 3
1 (14.3%)Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
Phase 3
Completed
- Conditions
- Arterial HypertensionAlbuminuria
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 43
- Registration Number
- NCT02376075
- Locations
- 🇩🇪
Profil Mainz GmbH & Co. KG, Mainz, Rhineland-Palatinate, Germany
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
Phase 4
- Conditions
- Diabetes Mellitus Type II
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 44
- Registration Number
- NCT01565096
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Germany
Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
Phase 4
- Conditions
- Insulin-requiring Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2011-12-29
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT01500850
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Rheinland-Pfalz, Germany
Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study
Phase 4
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2012-03-05
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 12
- Registration Number
- NCT01417897
- Locations
- 🇩🇪
ife GmbH, Clinic, Mainz, Rhineland-Palatinate, Germany
Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2011-03-15
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 44
- Registration Number
- NCT01208012
- Locations
- 🇩🇪
IKFE Institute for Clinical Research and Development, Mainz, Germany
- Prev
- 1
- 2
- Next
News
No news found